Abstract
With the promise of a potentially single-dose curative regimen, CAR-T cell therapies have brought a paradigm shift in the treatment and management of hematological malignancies with 6 approved products in the USA. However, there are no approved CAR-T cell therapies for solid tumors. Herein, we report the clinical pharmacology profile of AMG 119, the first CAR-T cell therapy targeting delta-like ligand 3 (DLL3), in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). AMG 119 demonstrated robust cellular expansion with long-lasting cell persistence and a favorable exposure–response relationship. AMG 119 has been demonstrated to be clinically safe and well tolerated at the doses tested, with no dose-limiting toxicities (DLTs) reported. This is the first publication of the clinical pharmacology profile of a CAR-T cell therapy in SCLC, with encouraging cellular kinetics data supporting the potential for CAR-T cell therapy in solid tumor space.
Original language | English (US) |
---|---|
Pages (from-to) | 362-370 |
Number of pages | 9 |
Journal | Journal of Clinical Pharmacology |
Volume | 64 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2024 |
Keywords
- CAR-T cell therapy
- cellular kinetics
- DLL3
- small cell lung cancer
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)